The project aims at revolutionising the treatment of glioblastoma (GBM), the most lethal tumour of the central nervous system, through a consistent implementation of personalised medicine. Currently available GBM management is standardised and non-curative, as it can only increase patients’ survival by a few months. Personalised care relies on the characterisation of the heterogeneity of glioblastomas in a close and reliable way, tailoring and adjusting the treatment continuously to overcome the tumour’s mechanisms of defence that invariably arise with time. The project focuses on the potential of extracellular vesicle-based liquid biopsy, with the goal to validate the extracellular vesicles as a diagnostic and prognostic biomarker, and as a follow-up tool, able to cope with the heterogeneity and mutability typical of glioblastomas. By proposing a multi-level characterization of all the informative power of these blood-derived vesicles, the project will analyse plasma extracellular vesicles concentration and molecular cargo (DNA, RNA, protein) during the whole disease course. In parallel, the project envisages a line of bioethical research where each patient is longitudinally followed for the entire history of his disease, in order to develop ethical tools to optimally implement the principles of personalised medicine in the treatment of glioblastomas and create the basis for potential applications in other cancers.